235 related articles for article (PubMed ID: 27292820)
1. Impact of anti-PEG IgM antibodies on the pharmacokinetics of pegylated asparaginase preparations in mice.
Poppenborg SM; Wittmann J; Walther W; Brandenburg G; Krähmer R; Baumgart J; Leenders F
Eur J Pharm Sci; 2016 Aug; 91():122-30. PubMed ID: 27292820
[TBL] [Abstract][Full Text] [Related]
2. Comparative pharmacokinetic/pharmacodynamic characterisation of a new pegylated recombinant E. coli L-asparaginase preparation (MC0609) in Beagle dog.
Borghorst S; Hempel G; Poppenborg S; Franke D; König T; Baumgart J
Cancer Chemother Pharmacol; 2014 Aug; 74(2):367-78. PubMed ID: 24934864
[TBL] [Abstract][Full Text] [Related]
3. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
[TBL] [Abstract][Full Text] [Related]
4. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
[TBL] [Abstract][Full Text] [Related]
5. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients.
Armstrong JK; Hempel G; Koling S; Chan LS; Fisher T; Meiselman HJ; Garratty G
Cancer; 2007 Jul; 110(1):103-11. PubMed ID: 17516438
[TBL] [Abstract][Full Text] [Related]
6. Impact of Pre-Existing or Induced Anti-PEG IgM on the Pharmacokinetics of Peginterferon Alfa-2a (Pegasys) in Mice.
Elsadek NE; Hondo E; Shimizu T; Takata H; Abu Lila AS; Emam SE; Ando H; Ishima Y; Ishida T
Mol Pharm; 2020 Aug; 17(8):2964-2970. PubMed ID: 32519877
[TBL] [Abstract][Full Text] [Related]
7. Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia.
Khalil A; Würthwein G; Golitsch J; Hempel G; Fobker M; Gerss J; Möricke A; Zimmermann M; Smisek P; Zucchetti M; Nath C; Attarbaschi A; Von Stackelberg A; Gökbuget N; Rizzari C; Conter V; Schrappe M; Boos J; Lanvers-Kaminsky C
Haematologica; 2022 Jan; 107(1):49-57. PubMed ID: 33299233
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Pre-existing IgG and IgM Antibodies against Polyethylene Glycol (PEG) in the General Population.
Yang Q; Jacobs TM; McCallen JD; Moore DT; Huckaby JT; Edelstein JN; Lai SK
Anal Chem; 2016 Dec; 88(23):11804-11812. PubMed ID: 27804292
[TBL] [Abstract][Full Text] [Related]
9. Impact of Antibodies Against Polyethylene Glycol on the Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukaemia: A Population Pharmacokinetic Approach.
Siebel C; Lanvers-Kaminsky C; Alten J; Smisek P; Nath CE; Rizzari C; Boos J; Würthwein G
Eur J Drug Metab Pharmacokinet; 2022 Mar; 47(2):187-198. PubMed ID: 34878584
[TBL] [Abstract][Full Text] [Related]
10. The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics.
Fernandes AI; Gregoriadis G
Int J Pharm; 2001 Apr; 217(1-2):215-24. PubMed ID: 11292557
[TBL] [Abstract][Full Text] [Related]
11. Measurement of Pre-Existing IgG and IgM Antibodies against Polyethylene Glycol in Healthy Individuals.
Chen BM; Su YC; Chang CJ; Burnouf PA; Chuang KH; Chen CH; Cheng TL; Chen YT; Wu JY; Roffler SR
Anal Chem; 2016 Nov; 88(21):10661-10666. PubMed ID: 27726379
[TBL] [Abstract][Full Text] [Related]
12. Impact of anti-PEG antibody affinity on accelerated blood clearance of pegylated epoetin beta in mice.
Chang TC; Chen BM; Wu JY; Cheng TL; Roffler S
Biomed Pharmacother; 2022 Feb; 146():112502. PubMed ID: 34891120
[TBL] [Abstract][Full Text] [Related]
13. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
Vieira Pinheiro JP; Wenner K; Escherich G; Lanvers-Kaminsky C; Würthwein G; Janka-Schaub G; Boos J
Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
[TBL] [Abstract][Full Text] [Related]
14. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
[TBL] [Abstract][Full Text] [Related]
15. Pegaspargase: A Review in Acute Lymphoblastic Leukaemia.
Heo YA; Syed YY; Keam SJ
Drugs; 2019 May; 79(7):767-777. PubMed ID: 31030380
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase.
Chien WW; Allas S; Rachinel N; Sahakian P; Julien M; Le Beux C; Lacroix CE; Abribat T; Salles G
Invest New Drugs; 2014 Oct; 32(5):795-805. PubMed ID: 24829072
[TBL] [Abstract][Full Text] [Related]
17. Anti-PEG IgM Is a Major Contributor to the Accelerated Blood Clearance of Polyethylene Glycol-Conjugated Protein.
Mima Y; Hashimoto Y; Shimizu T; Kiwada H; Ishida T
Mol Pharm; 2015 Jul; 12(7):2429-35. PubMed ID: 26070445
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of recombinant asparaginase in children with acute lymphoblastic leukemia.
Völler S; Pichlmeier U; Zens A; Hempel G
Cancer Chemother Pharmacol; 2018 Feb; 81(2):305-314. PubMed ID: 29204688
[TBL] [Abstract][Full Text] [Related]
19. Pegaspargase: an alternative?
Holle LM
Ann Pharmacother; 1997 May; 31(5):616-24. PubMed ID: 9161659
[TBL] [Abstract][Full Text] [Related]
20. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia.
Panetta JC; Gajjar A; Hijiya N; Hak LJ; Cheng C; Liu W; Pui CH; Relling MV
Clin Pharmacol Ther; 2009 Dec; 86(6):651-8. PubMed ID: 19741605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
